Representative Publications
a complete listing can be found here.
Select year of interest:
2014

Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance.
Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H, Ince TA, Drage MG, Dering J, Konecny GE, Matulonis U, Mills GB, Slamon DJ, Drapkin R.*, Brugge JS*.
* co-corresponding
J Clin Invest (2014); 124: 2611-25.

Article Coverage and Highlights Gynecol Oncol
Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women.
Karlan BY, Thorpe J, Watabayashi K, Drescher CW, Palomares M, Daly MB, Paley P, Hillard P, Andersen MR, Anderson G, Drapkin R., Urban N.
Cancer Epidemiol Biomarkers Prev (2014); 23: 1383-93.
The hormonal composition of follicular fluid and its implications for ovarian cancer pathogenesis.
Emori MM, Drapkin R.
Reprod Biol Endocrinol (2014); 12: 60.

Highlights from the 2014 American Association for Cancer Research Annual Meeting.
Bowtell DD, Drapkin R.
Gyn Oncol (2014); 134: 3-5.

Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors.
Labidi-Galy S, Clauss A, Ng V, Duraisamy S, Elias KM, Piao H-Y, Bilal E, Davidowitz RA, Lu Y, Badalian-Very G, Gyorffy B, Kang U-B, Ficarro S, Ganesan S, Mills GB, Marto JA, Drapkin R.
Oncogene, in press.
In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene.
Dunn GP, Cheung HW, Agarwalla PK, Zektser Y, Karst AM, Boehm JS, Weir BA, Berlin AM, Zou L, Getz G, Liu JF, Hirsch MS, Vazquez F, Root DE, Beroukhim R, Drapkin R, Hahn WC.
PNAS (2014); 111: 1102-7.
Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.
Karst AM, Jones PM, Vena N, Ligon AH, Liu JF, Hirsch MS, Etemadmoghadam D, Bowtell DD, Drapkin R.
Cancer Res (2014); 74: 1141-52.
Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms.
Elias KM, Labidi-Galy SI, Vitonis AF, Hornick JL, Doyle LA, Hirsch MS, Cramer DW, Drapkin R.
Gynecol Oncol (2014); 132: 328-33.
FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis.
Levanon K, Sapoznik S, Bahar-Shany K, Brand H, Shapira-Frommer R, Korach J, Hirsch MS, Roh MH, Miron A, Liu JF, Vena N, Ligon AH, Fotheringham S, Bailey D, Flavin RJ, Birrer MJ, Drapkin R.
Oncogene (2014) [Epub ahead of print].
2013

Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca; Tp53; Pten models.
Perets R, Wyant GA, Muto, Bijron JG, Poole BB, Chin KT, Chen JYH, Ohman AW, Stepule CD, Kwak S, Karst AM, Hirsch MS, Setlur SR, Crum CP, Dinulescu DM, Drapkin R.
Cancer Cell (2013); 24: 751-765.

Article Coverage and Highlights Gynecol Oncol | Gynecol Oncol | Gynecol Oncol
Coming into focus: the nonovarian origins of ovarian cancer.
Dubeau L and Drapkin R.
Annals of Oncology (2013); 24 (Suppl 8): viii28-viii35.
Modeling high-grade serous carcinoma: how converging insights into pathogenesis and genetics are driving better experimental platforms.
Jones PM, Drapkin R,
Front. Oncol. (2013); 3:217. doi: 10.3389/fonc.2013.00217
HE4 (WFDC2) promotes tumor growth in endometrial cancer cell lines.
Li J, Chen H, Mariani A, Chen D, Klatt E, Podratz K, Drapkin R, Broaddus R, Dowdy S, Jiang S-W.
Int J Mol Sci 2013; 14: 6026-6043.
Human epididymis protein 4 is up-regulated in gastric and pancreatic adenocarcinomas.
O’Neal RL, Nam KT, LaFleur BJ, Barlow B, Nozaki K, Lee H-J, Kim WH, Yang H-K, Shi C, Maitra A, Montgomery E, Washington MK, El Rifai W, Drapkin RI, Goldenring JR.
Human Pathol 2013; 44: 734-742.
Promoter methylation of the SALL2 tumor suppressor gene in ovarian cancers.
Sung CK, Li D, Andrews E, Drapkin R, Benjamin T.
Mol Oncol (2013); 7: 419-427.
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.
Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, Fereday S, Lawrence M, Carter SL, Mermel CH, Kostic AD, Etemadmoghadam D, Saksena G, Cibulskis K, Duraisamy S, Levanon K, Sougnez C, Tsherniak A, Gomez S, Onofrio R, Gabriel S, Chin L, Zhang N, Spellman PT, Zhang Y, Akbani R, Hoadley KA, Kahn A, Kobel M, Huntsman D, Soslow RA, Defazio A, Birrer MJ, Gray JW, Weinstein JN, Bowtell DD, Drapkin R, Mesirov JP, Getz G, Levin DA, Meyerson M.
J Clin Invest (2013); 123: 517-25.
Stathmin-1 expression as a complement to p16 helps identify high-grade cervical intraepithelial neoplasia with increased specificity.
Howitt BE, Nucci MR, Drapkin R, Crum CP, Hirsch MS.
Am J Surg Pathol (2013); 37: 89-97.
2012
The Polyoma Virus Large T Binding Protein p150 Is a Transcriptional Repressor of c-MYC.
Sung CK, Yim H, Gu H, Li D, Andrews E, Duraisamy S, Li C, Drapkin R, Benjamin T.
PLoS One (2012); 7(9): e46486.
Primary culture and immortalization of human fallopian tube secretory epithelial cells.
Karst AM, Drapkin R.
Nature Protocols (2012); 7: 1755-1764.
Targeted Tumor-Penetrating siRNA Nanocomplexes for Credentialing the Ovarian Cancer Oncogene ID4.
Ren Y, Cheung HW, von Maltzhan G, Agrawal A, Cowley GS, Weir BA, Boehm JS, Tamayo P, Karst AM, Liu JF, Hirsch MS, Mesirov JP, Drapkin R, Root DE, Lo J, Fogal V, Ruoslahti E, Hahn WC, Bhatia SN.
Science Transl. Med. (2012); 4: 147ra112.
Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome.
Wang ZC, Birkbak NJ, Culhane A, Drapkin RI, Fatima A, Tian R, Schwede M, Alsop K, Daniels KE, Piao H, Liu J, Etemadmoghadam D, Miron A, Salvesen HB, Mitchell G, Defazio A, Quackenbush J, Berkowitz RS, Iglehart JD, Bowtell DD, Matulonis UA.
Clin Cancer Res (2012); 18: 5806-5815
Angiogenic mRNA and microRNA Gene Expression Signature Predicts a Novel Subtype of Serous Ovarian Cancer.
Bentink S, Haibe-Kains B, Risch T, Fan JB, Hirsch MS, Holton K, Rubio R, April C, Chen J, Wickham-Garcia E, Liu J, Culhane A, Drapkin R, Quackenbush J, Matulonis UA.
PLoS One. (2012); 7(2): e30269.
Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome.
Engler DA, Gupta S, Growdon WB, Drapkin RI, Nitta M, Sergent PA, Allred SF, Gross J, Deavers MT, Kuo WL, Karlan BY, Rueda BR, Orsulic S, Gershenson DM, Birrer MJ, Gray JW, Mohapatra G.
PLoS One. (2012); 7(2): e30996.
The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer.
Manchanda R, Drapkin R, Jacobs I, Menon U.
Gynecol Oncol (2012) 124:185-91.
ErbB2, EphrinB1, Src Kinase and PTPN13 Signaling Complex Regulates MAP Kinase Signaling in Human Cancers.
Vermeer PD, Bell M, Lee K, Vermeer DW, Wieking BG, Bilal E, Bhanot G, Drapkin RI, Ganesan S, Klingelhutz AJ, Hendriks WJ, Lee JH.
PLoS One. (2012); 7(1):e30447.
2011
The new face of ovarian cancer modeling: better prospects for detection and treatment.
Karst AM, Drapkin R.
Faculty 1000 Med Rep (2011) 3:22.

Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy.
Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, Deng J, Anderson KC, Richardson P, Tai YT, Mitsiades CS, Matulonis UA, Drapkin R, Stone R, Deangelo DJ, McConkey DJ, Sallan SE, Silverman L, Hirsch MS, Carrasco DR, Letai A.
Science (2011) 334:1129-33.

Rethinking ovarian cancer: recommendations for improving outcomes.
Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC,Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR.
Nature Reviews Cancer (2011) 11: 719-725.
Aberrant Expression of the Dendritic Cell Marker TNFAIP2 by the Malignant Cells of Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma Distinguishes These Tumor Types From Morphologically and Phenotypically Similar Lymphomas.
Kondratiev S, Duraisamy S, Unitt CL, Green MR, Pinkus GS, Shipp MA, Kutok JL, Drapkin R, Rodig SJ.
Am J Surg Pathol (2011) 35: 1531-9.
High Throughput Interrogation of Somatic Mutations in High Grade Serous Cancer of the Ovary.
Matulonis UA, Hirsch M, Palescandolo E, Kim E, Liu J, van Hummelen P, MacConaill L, Drapkin R, Hahn WC.
PLoS ONE (2011) 6(9): e24433.

Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas.
Karst AM, Levanon K, Duraisamy S, Liu JF, Hirsch MS, Hecht JL, Drapkin R.
Gynecol Oncol (2011) 123: 5-12
.

Article Coverage and Highlights Gynecol Oncol  
Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer.
Cheung HW, Cowley GS, Weir BA, Boehm JS, Rusin S, Scott JA, East A, Ali LD, Lizotte PH, Wong TC, Jiang G, Hsiao J, Mermel CH, Getz G, Barretina J, Gopal S, Tamayo P, Gould J, Tsherniak A, Stransky N, Luo B, Ren Y, Drapkin R., Bhatia SN, Mesirov JP, Garraway LA, Meyerson M, Lander ES, Root DE, Hahn WC.
PNAS (2011) 108:12372-7.

Modeling high-grade serous ovarian carcinogenesis from the fallopian tube.
Karst AM, Levanon K, Drapkin R.
PNAS (2011) 108: 7547-7552.

Article Coverage and Highlights Inside The Institute | Nature Cancer Review | JNCI

Ex vivo culture of primary human fallopian tube epithelial cells.
Fotheringham S, Levanon K, Drapkin R.
J Vis Exp (2011) 51: http://www.jove.com/details.stp?id=2728 doi: 10.3791/2728
.

Article Coverage and Highlights Jove Link  
A comprehensive analysis of Pax8 expression in human epithelial tumors.
Laury A, Perets R, Piao H, Krane JF, Barletta JA, French C, Chirieac LR, Lis R,
Loda M, Hornick JL, Drapkin R, Hirsch MS.
Am J Surg Pathol (2011) 35: 816-826.